Inflammation as a Hidden Driver of Heart Disease
For decades, the dominant narrative of cardiovascular disease centred on cholesterol — a waxy villain clogging arteries, a problem to be solved by statins and dietary restraint. That narrative, while not wrong, has always been incomplete. Emerging from decades of painstaking research is a parallel and equally urgent story: chronic, low-grade inflammation may be as powerful a driver of heart attacks and strokes as any lipid panel your doctor has ever ordered.
The inflammatory hypothesis of cardiovascular disease did not arrive suddenly. As early as the 1990s, pathologists noted that atherosclerotic plaques — the fatty deposits that narrow arteries and rupture catastrophically — were not passive accumulations of lipid, but living sites of immune activity. White blood cells, cytokines, and inflammatory proteins such as C-reactive protein (CRP) were found embedded in these plaques, suggesting that the arterial wall was engaged in a chronic, smouldering battle with its own immune system.
The landmark CANTOS trial in 2017 provided the first decisive clinical proof. It demonstrated that canakinumab, a monoclonal antibody targeting interleukin-1β — a master inflammatory signalling molecule — reduced major adverse cardiovascular events in high-risk patients, independent of any change in cholesterol levels. The implications were seismic: inflammation was not merely a companion to cardiovascular risk, it was a cause.
High-sensitivity CRP (hsCRP) has since emerged as a biomarker of particular clinical weight. Research now shows that hsCRP is at least as strong a predictor of future cardiovascular events as traditional lipoproteins — a finding that has prompted the European Society of Cardiology’s 2024 Guidelines for Chronic Coronary Syndrome to formally recommend targeted anti-inflammatory therapy for patients with elevated residual inflammatory risk even when lipid levels are adequately controlled.
But the most dramatic development is the resurgence of a drug that has been used for centuries in a completely different context: colchicine. Derived from the autumn crocus and long employed to treat gout and pericarditis, low-dose colchicine (0.5 mg daily) has now been shown, through multiple rigorous randomised controlled trials including COLCOT and LoDoCo2, to significantly reduce the risk of myocardial infarction and other major cardiovascular events. A 2025 Cochrane systematic review incorporating data from 22,153 participants across eight studies confirmed with high certainty that low-dose colchicine reduces MI risk by approximately 26 percent.
The drug works by disrupting microtubule polymerisation in immune cells, inhibiting the NLRP3 inflammasome and downstream cytokine cascades, thereby dampening the precise inflammatory pathway that destabilises arterial plaques. It is taken orally, costs a fraction of newer biological therapies, and has a well-characterised safety profile, albeit requiring caution in patients with significant renal or hepatic dysfunction.
The US Food and Drug Administration approved low-dose colchicine for cardiovascular risk reduction in 2024, and the American Heart Association/American College of Cardiology has assigned it a Class 2a recommendation for patients with chronic stable coronary artery disease. Despite this, clinical uptake remains conspicuously limited — a gap that cardiologists and public health researchers are working urgently to close.
What makes the inflammation story particularly sobering is that it operates silently. Patients without elevated cholesterol, without hypertension, without diabetes — patients who believe themselves insulated from cardiac risk — may carry persistently elevated hsCRP, driven by sedentary lifestyles, chronic stress, subclinical infections, or metabolic dysfunction, and face a significantly elevated hazard that standard risk calculators fail to capture.
The prescription for the future is clear: routine hsCRP screening, not as an afterthought but as a standard of cardiovascular care, and swift deployment of affordable anti-inflammatory therapy where elevated inflammatory risk is confirmed. The inflammation hypothesis has graduated from hypothesis to evidence-based framework. The question now is not whether inflammation matters to the heart — it unquestionably does — but how quickly the global clinical community will integrate this knowledge into everyday practice. The fire in the arterial wall has been burning long before symptoms appear. Medicine must learn to read the smoke.
– Dr Srinayana Kavuri




